IOWA | Health and Human Services

Iowa Medicaid Drug Utilization Review (DUR) Commission

February 4, 2026

Meeting Format: Virtual

Time: 9:30 a.m. – 1:30 p.m.

Teams Meeting: https://teams.microsoft.com/l/meetup-join/19%3ameeting_ZjQyYjk0MTEtYmM4OS00Y2E1LWJhNzEtMDY1OTQ1NDFiMGNh%40thread.v2/0?context=%7b%22Tid%22%3a%228d2c7b4d-085a-4617-8536-38a76d19b0da%22%2c%22Oid%22%3a%22982a0572-2333-4ea7-b2e0-b02af2367c61%22%7d

Meeting ID: 267 449 359 878 25
Passcode: 2aw6us2u

Tentative Agenda

1. Welcome & Introductions
    a) Commission Members and Staff
2. Commission Business
    a) Approval of November 5, 2025 Meeting Minutes
    b) November 2025 DUR Recommendation Letter to DHHS
    c) Follow-Up from Previous Meeting(s)
3. Iowa Medicaid Pharmacy Update
4. Prevalence Report Summaries
    a) Molina Healthcare of Iowa
    b) Wellpoint Iowa
    c) Fee-for-Service
    d) Iowa Total Care
    e) Comparative Summary
5. Public Comment* (Complete Speaker Conflict of Interest Disclosure Form)
    - Verbal - Must **pre-register** to provide verbal public comment and submit a completed conflict of interest disclosure. Must indicate if will be in-person or virtual testimony. Five (5) minute maximum limit.
    - Written – Must submit written comments and a completed conflict of interest disclosure,
    - **All submissions must be received no later than 4:30 p.m. CT January 28, 2026.**
    - **Send to pba_iadur@optum.com. Indicate in email if providing written or verbal comment.**
6. Retrospective DUR
    a) Data Presentation(s)
        i. Duplicate Short-Acting Opioids
        ii. Bisphosphonate Drug Holiday
    b) Proposal(s)
        i. Adherence to Antipsychotic Medications in Patients with Schizophrenia
        ii. Evaluation of the use of Duplicate Therapy for Autoimmune Disorders
    c) Commission Recommendations for Retrospective DUR Agenda Topics
7. Break (10 minutes)
8. Prior Authorization

a) Dupilumab (Dupixent)
b) Finerenone (Kerendia)
c) Janus Kinase Inhibitors
d) Remibrutinib (Rhapsido)
e) Tezepelumab-ekko (Tezspire)

9. Miscellaneous
   a) DUR Digest Vol. 38, No. 1 – Second Review
10. MedWatch
    HHS Removes Misleading FDA Warnings on Hormone Replacement Therapy
    FDA approves 1st drug for children 7 years and older with irritable bowel syndrome with constipation
    FDA approves drug for type of abnormally fast heart rhythm
    FDA Approves Drug to Treat Chronic, Progressive Lung Disease
    FDA approves first oral treatment for anemia in thalassemia
11. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Any individual speaking, presenting, or providing written comment must register and complete a conflict-of-interest disclosure. Registration and completed forms must be provided to DUR staff at least one week prior to the scheduled meeting at pba_iadur@optum.com. Failure to register and submit a complete conflict-of-interest disclosure form by the specified date and time will result in a delay in your comments being considered until the next scheduled meeting. Reference complete public comment policy here.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at pba_iadur@optum.com or (515) 974-3131.

Next Meeting
May 6, 2026
Meeting Format: Virtual